For tirzepatide, subcutaneous administration is required
Injectable BPC-157 is widely considered the most effective delivery method for targeted, systemic results
Thereby, it is important to indicate that with consistently less nerve damage in all damaged areas in all BPC 157-cuprizone rats, the most important evidence is the consistent beneficial effect of BPC 157 also in those areas that were most affected, and thereby markedly improved gross presentation and functions in BPC 157 rats
This documentation helps identify what works best for your individual response and catches any negative trends early
The FDA lists BPC-157 as a Category 2 bulk drug substance, which limits where it can be legally compounded
Currently, however, there is no broader research in this area